SKYE BIOSCIENCE INC (SKYE) Stock Price, Forecast & Analysis
USA - NASDAQ:SKYE - US83086J2006 - Common Stock
SKYE Key Statistics, Chart & Performance
The current stock price of SKYE is 1.37 USD. In the past month the price decreased by -5.52%. In the past year, price decreased by -72.32%.
SKYE Latest News, Press Relases and Analysis
SKYE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About SKYE
Company Profile
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Company Info
SKYE BIOSCIENCE INC
11250 El Camino Real, Suite 100
San Diego CALIFORNIA US
Employees: 16
Phone: 18584100266
SKYE BIOSCIENCE INC / SKYE FAQ
What does SKYE do?
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
What is the current price of SKYE stock?
The current stock price of SKYE is 1.37 USD. The price decreased by -9.87% in the last trading session.
Does SKYE stock pay dividends?
SKYE does not pay a dividend.
What is the ChartMill rating of SKYE BIOSCIENCE INC stock?
SKYE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does SKYE BIOSCIENCE INC have?
SKYE BIOSCIENCE INC (SKYE) currently has 16 employees.
What is SKYE BIOSCIENCE INC worth?
SKYE BIOSCIENCE INC (SKYE) has a market capitalization of 42.46M USD. This makes SKYE a Nano Cap stock.
When does SKYE BIOSCIENCE INC (SKYE) report earnings?
SKYE BIOSCIENCE INC (SKYE) will report earnings on 2026-03-18, after the market close.
SKYE Technical Analysis
SKYE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SKYE. No worries on liquidiy or solvency for SKYE as it has an excellent financial health rating, but there are worries on the profitability.
SKYE Financial Highlights
Over the last trailing twelve months SKYE reported a non-GAAP Earnings per Share(EPS) of -3.31. The EPS increased by 72.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.24% | ||
| ROE | -97.02% | ||
| Debt/Equity | 0 |
SKYE Forecast & Estimates
14 analysts have analysed SKYE and the average price target is 8.89 USD. This implies a price increase of 548.8% is expected in the next year compared to the current price of 1.37.